LENOIR, N.C.--(BUSINESS WIRE)--Greer, a leading developer and provider of allergy immunotherapy products and services, announced today that findings from its Phase I safety and dosing clinical trials in sublingual-oral immunotherapy have been published in the March issue of the Annals of Allergy, Asthma and Immunology. The studies were conducted to determine the safety and tolerability of the sublingual-oral administration of Greer’s standardized dust mite, short ragweed, Timothy grass and cat hair extracts. Robert Esch, Ph.D., Executive Vice President of Research and Development for Greer, was the principal investigator.
